The default mode network has occupied a central place in cognitive neuroscience since its discovery in the early 2000s, when positron emission tomography and, later, functional magnetic resonance imaging revealed a set of regions that consistently decrease their activity during demanding external tasks and increase it during quiet rest. This network, anchored in the medial prefrontal cortex, the posterior cingulate cortex, the precuneus, and the inferior parietal lobule, is thought to support autobiographical memory retrieval, envisioning the future, self-referential processing, and mind-wandering. In schizophrenia, decades of imaging work have documented disruptions in this network’s connectivity, which have been linked to disturbances in self-monitoring, hallucination severity, and disorganized thought. What the new study adds is a bridge between this circuitry and one of the most consequential health behaviors in the disorder: smoking.

The researchers approached the question using resting-state functional connectivity analysis, a technique that measures the degree to which spatially distributed brain regions fluctuate together in their blood-oxygen-level-dependent signals while participants lie quietly in the scanner. Synchronized low-frequency fluctuations are interpreted as a signature of functional coupling, even though they do not directly measure anatomical wiring. By parcellating the cortex and extracting connectivity profiles associated with the default mode network, the team was able to quantify how strongly parietal nodes of this circuit communicated with the rest of the network and with other major systems, including the frontoparietal control network and the salience network, which are implicated in cognitive control and in switching between internal and external attention.

Across the study sample, the strength of parietal default mode connectivity emerged as a statistically reliable correlate of tobacco use measures, which for many participants included biologically verified indicators such as cotinine levels, the primary metabolite of nicotine, rather than relying solely on self-report. This methodological point matters enormously. Self-reported smoking in psychiatric populations is notoriously unreliable, shaped by stigma, recall difficulty, and cognitive impairment, and studies that depend on it risk both overestimation and underestimation of true exposure. By anchoring the smoking phenotype in objective biochemical measures where available, the analysis strengthens the claim that the brain-behavior association is genuine rather than an artifact of reporting bias.

Why should a network associated with daydreaming and self-referential thought care about nicotine? One plausible explanation lies in the interplay between the default mode network and dopaminergic signaling. Nicotine acts on nicotinic acetylcholine receptors that modulate dopamine release in the mesolimbic pathway, the reward circuitry that reinforces drug-taking. In psychosis, this dopaminergic system is already dysregulated, with the prevailing neurobiological models of schizophrenia positing aberrant striatal dopamine synthesis and release as a proximate cause of positive symptoms. Nicotine’s ability to transiently normalize aspects of this signaling, or to dampen sensory gating deficits, has long been cited in self-medication accounts. The new findings suggest that individual differences in the intrinsic organization of the default mode network may reflect, or even partly determine, the degree to which nicotine exerts reinforcing and normalizing effects in a given brain.

A complementary interpretation comes from the cognitive domain. The default mode network and the frontoparietal control network are engaged in a dynamic antagonist relationship: when the former is active, the latter is typically suppressed, and effective cognitive performance requires the orchestration of switching between internally and externally directed states. Smoking initiation and maintenance depend on executive functions, including the capacity to inhibit impulses, delay gratification, and weigh long-term health consequences against immediate relief. If parietal default mode connectivity indexes the rigidity of internal focus or the difficulty of disengaging from internally generated thought, then individuals with stronger or atypical coupling may find external, health-protective control processes harder to deploy, making tobacco use more likely to persist. In this framing, connectivity is not a cause of smoking in a simple causal chain but a marker of the neurocognitive soil in which the behavior takes root.

The psychosis context amplifies both the scientific and clinical significance of these results. Roughly three-quarters of people with schizophrenia who smoke do so heavily, and smoking accounts for the majority of the excess mortality observed in the disorder. Yet smokers with psychosis are less likely to receive smoking cessation counseling, less likely to be prescribed pharmacotherapy such as varenicline or bupropion, and more likely to relapse after quitting attempts. If neural measures such as default mode connectivity could stratify patients by the likely neurobiological drivers of their smoking, clinicians might eventually tailor interventions accordingly, deploying more intensive combined behavioral and pharmacological strategies for those whose circuit profiles indicate a strongly entrenched pattern. The present study does not yet support such clinical deployment, but it supplies the kind of mechanistic correlate that personalized approaches require.

As with all resting-state connectivity research, important caveats frame the interpretation. Functional connectivity is correlational; the cross-sectional design of the analysis cannot determine whether atypical parietal connectivity predisposes individuals to smoking, whether chronic nicotine exposure reshapes the network over time, or whether both are downstream of a third factor such as illness severity, medication exposure, or shared genetic risk. Longitudinal designs, within-person repeated imaging, and causal modeling techniques, including studies in animal models where nicotine exposure can be experimentally controlled, will be needed to disentangle these possibilities. Sample heterogeneity, medication effects, and the modest effect sizes typical of brain-wide association studies further caution against overreading any single result. Still, the consistency of the default mode network’s involvement across cognitive, symptomatic, and now behavioral domains in psychosis builds a cumulative case that this circuit is a genuine hub of individual difference in the disorder.

For the broader field, the study exemplifies a trend in psychiatric neuroscience toward connecting large-scale intrinsic brain organization with real-world health behaviors, rather than with abstract laboratory measures alone. Smoking is among the most modifiable risk factors in severe mental illness, and understanding its neural correlates is a step toward interventions that could meaningfully extend lives. The finding that the brain’s daydreaming circuitry carries information about tobacco use in psychosis is a reminder that even the most habitual and seemingly volitional behaviors are embedded in the biology of the disorders themselves, and that dismantling smoking’s grip on this vulnerable population may ultimately require working with, rather than around, the architecture of the psychotic brain.

Subject of Research: Resting-state parietal default mode network functional connectivity and its association with tobacco use in psychotic disorders

Article Title: Parietal default mode network connectivity is associated with tobacco use in psychosis

Article References: Parietal default mode network connectivity is associated with tobacco use in psychosis. (n.d.). https://doi.org/10.1038/s41537-026-00797-0

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00797-0

Keywords: schizophrenia, psychosis, default mode network, tobacco use, nicotine, functional connectivity, resting-state fMRI, neuroimaging, dopamine, smoking cessation, parietal cortex, severe mental illness

This novel research delves into the intersection of smoking-induced inflammation and autoimmune pathology in RA, with a particular focus on the abnormal activation of platelets—a component traditionally associated with thrombosis but now increasingly recognized as an influential player in inflammatory diseases. Chronic cigarette smoke exposure, the study reveals, drives hyperactivation of platelets, which in turn potentiates the inflammatory cascade characteristic of RA. This vicious cycle of inflammation and platelet activation appears to underlie much of the clinical deterioration observed in patients who smoke, positioning platelets as both culprits and potential targets for intervention.

Integral to the study’s innovation is the investigation of 3,3′-diindolylmethane (DIM), a natural phytochemical derived from cruciferous vegetables, celebrated for its anti-inflammatory and anticancer properties. The authors meticulously explore DIM’s capacity to counteract smoking-induced platelet hyperactivity and subsequent inflammatory amplification in a collagen-induced arthritis (CIA) mouse model. Their findings herald DIM as a compelling candidate for preventing or mitigating RA exacerbations triggered by smoke exposure, thus opening new frontiers in nutritional immunomodulation.

The pathological analysis conducted in CIA mice exposed to cigarette smoke reveals striking amelioration of inflammation following DIM treatment. Histological examination uncovered that DIM not only reduced synovial hyperplasia and leukocyte infiltration but also dampened the aggressive pannus formation that typically characterizes RA progression. Importantly, these beneficial effects correlated tightly with a reduction in markers of platelet abnormal activation, underscoring the tight mechanistic linkage between platelet biology and joint inflammation.

On a cellular and molecular level, the researchers documented a surrogate set of hallmarks emblematic of smoke-driven platelet dysfunction. Cigarette smoke extract (CSE) exposure incited a robust upregulation of CD62p—a critical marker of platelet activation—alongside dysregulated intracellular calcium signaling, excessive generation of reactive oxygen species (ROS), and a worrisome decline in mitochondrial membrane potential (ΔΨm). These events collectively signify heightened platelet reactivity and metabolic stress, which contribute to the perpetuation of an inflammatory milieu.

Conversely, DIM was shown to effectively suppress these aberrant processes in vitro. Treatment with DIM restored mitochondrial function and attenuated calcium overload, thereby curbing ROS production and reducing CD62p surface expression. This multifaceted inhibition of platelet hyperactivation by DIM pinpoints mitochondria and intracellular signaling as key targets, unraveling a complex biochemical pathway exploited by cigarette smoke to propagate inflammation.

Crucially, the study elucidates that DIM mediates its protective effects by modulating two intertwined intracellular signaling cascades: the MAPK/NF-κB and PI3K/Akt/mTOR pathways. Both pathways are notorious for their roles in inflammatory gene expression, cell survival, and metabolic regulation. In platelets subjected to cigarette smoke stimuli, DIM attenuated the phosphorylation states of several nodal proteins within these signaling hubs, thereby disrupting the feed-forward amplification loop of platelet activation and immune cell recruitment.

The study’s emphasis on platelet-centered signaling offers a paradigm shift in understanding RA pathogenesis, traditionally viewed through the lens of lymphocyte-driven autoimmunity. By positioning platelet hyperactivation as an amplifier of joint inflammation in smoke-exposed RA, this research advocates targeting platelet signaling pathways as a complementary strategy alongside existing immunosuppressive therapies.

Beyond the mechanistic insights, the translational implications of this work are profound. DIM, as a naturally derived phytochemical with an established nutraceutical safety profile, could readily be integrated into preventive regimens aimed at individuals exposed to cigarette smoke or those genetically predisposed to RA. This nutritional approach offers a low-risk adjunct to conventional treatments, potentially curbing disease flares triggered or worsened by environmental insults.

The study also highlights the broader relevance of platelet biology in chronic inflammatory diseases beyond RA. Given that smoking is a risk factor for multiple vascular and autoimmune conditions, targeting platelet activation with agents like DIM may have far-reaching therapeutic benefits. Future research may investigate DIM’s effectiveness across diverse pathologies characterized by inflammation and aberrant platelet function.

Methodologically, the use of the CIA mouse model combined with cigarette smoke exposure provides a robust platform to mimic the human disease phenotype. The integration of in vivo and in vitro experiments strengthens the validity of the findings, demonstrating consistent DIM efficacy across systems. Moreover, state-of-the-art biochemical assays for mitochondrial function, ROS dynamics, and intracellular calcium fluxes lend unprecedented granularity to the mechanistic understanding.

This study’s revelations also rekindle interest in nutritional immunology, where diet-derived compounds exert tangible influences on immune regulation and disease modulation. DIM’s dual role in mitochondrial protection and signaling inhibition distinguishes it as a promising immunonutrient worthy of further clinical exploration in RA patients, particularly those burdened by smoking-related disease amplification.

Despite these promising outcomes, the authors acknowledge several limitations warranting future investigation. While the CIA model recapitulates many features of human RA, translational studies in patient cohorts remain essential. Additionally, the long-term safety and optimal dosing of DIM require thorough evaluation. Further deciphering DIM’s interaction with other immune cells will also enrich our understanding of its holistic anti-inflammatory capabilities.

In conclusion, this pioneering research firmly establishes abnormal platelet activation as a central mediator of smoking-exacerbated RA inflammation, while unveiling DIM as an effective inhibitor of this pathological process. These findings not only broaden our knowledge of RA pathophysiology but also illuminate a novel, nutrition-based therapeutic avenue that could attenuate disease severity in smokers. By targeting platelet signaling pathways at the crossroads of environmental exposure and genetic susceptibility, DIM offers a beacon of hope for millions grappling with this chronic autoimmune affliction.

The implications extend beyond RA, pointing towards a future where dietary phytochemicals play integral roles in controlling inflammation and enhancing patient outcomes across autoimmune and inflammatory spectra. As the scientific community continues unraveling the complexities of immune regulation, the modulation of platelet function stands out as an uncharted yet vital frontier ripe for innovation. Harnessing the power of natural compounds like DIM may well revolutionize how we conceptualize prevention and treatment of inflammation-driven diseases in the 21st century.

Subject of Research: Investigation of 3,3′-diindolylmethane (DIM) in preventing smoking-induced platelet abnormal activation and inflammation amplification in rheumatoid arthritis.

Article Title: Abnormal activation of platelets and inflammation in smoking-induced rheumatoid arthritis is alleviated by 3,3′-diindolylmethane.

Article References:
Cai, B., You, Y., Huang, L. et al. Abnormal activation of platelets and inflammation in smoking-induced rheumatoid arthritis is alleviated by 3,3′-diindolylmethane. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00360-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41435-025-00360-4

Led by Eleanor Kate Phillips and senior author Dawn L. DeMeo of Brigham and Women’s Hospital and Harvard Medical School, the investigation enrolled over 2,600 adults between ages 45 and 80, all with a minimum 10 pack-year smoking history. Unlike previous studies focused solely on individuals with diagnosed chronic obstructive pulmonary disease (COPD), this study uniquely incorporated participants with varying degrees of lung function, including many who exhibited no overt airflow obstruction at baseline. The central goal was to determine whether frailty status—categorized as robust, prefrail, or frail—exerts independent prognostic value in forecasting respiratory exacerbations and mortality risk.

Frailty was operationalized using a comprehensive clinical frailty index, capturing deficits in factors such as physical performance, comorbidity burden, and self-reported health. Over a three-year follow-up, the study meticulously documented the frequency and severity of respiratory exacerbations, commonly defined as acute worsening of symptoms like dyspnea, cough, and sputum production necessitating medical intervention. Significantly, the findings demonstrated that frail individuals faced a three- to five-fold increase in odds of severe or frequent respiratory attacks compared to those classified as robust, underscoring frailty as a potent, independent risk factor transcending traditional spirometric measures.

One of the study’s most striking revelations was that even participants in the prefrail stage—representing a prodromal phase of declining physiological resilience—displayed elevated risks for respiratory complications and death. This suggests that frailty exists on a continuum and that early identification and intervention could meaningfully alter clinical trajectories. The research also highlighted that many frail individuals maintained normal lung function according to standard tests, meaning that traditional pulmonary function tests (PFTs) alone may be insufficient for comprehensive risk assessment in smokers.

At the molecular level, the study delved into the relationship between frailty and biological aging through the lens of epigenetic biomarkers. Using DunedinPACE, a cutting-edge DNA methylation-based measure of the pace of aging, researchers observed accelerated epigenetic aging profiles among frail participants. These data suggest that systemic biological aging processes—reflected in epigenetic alterations—may underpin the vulnerability to respiratory exacerbations and mortality beyond the mechanical impairments captured by spirometry. The implication is profound: frailty may be a phenotypic manifestation of accelerated biological aging, linking systemic health decline to pulmonary vulnerability.

These insights carry significant clinical implications, particularly in illuminating the limitations of relying solely on traditional lung function parameters for risk stratification. Frailty screening—incorporating clinical assessments of strength, gait speed, and comorbidity grading—emerges as a vital tool in identifying at-risk populations among current and former smokers. This is especially important since a substantial subset of frail smokers demonstrate normal spirometry yet harbor a hidden vulnerability to serious exacerbations and premature mortality.

Furthermore, the study advocates for the integration of frailty evaluation into clinical workflows to guide preventive strategies. Timely identification of frailty may trigger interventions such as pulmonary rehabilitation, nutritional optimization, and tailored pharmacotherapy aimed at bolstering physiological reserves and reducing exacerbation risk. These approaches could potentially mitigate hospitalizations, improve quality of life, and extend survival in this at-risk population.

The findings also have broader public health relevance, emphasizing the need for comprehensive frailty screening programs alongside smoking cessation efforts. Considering that frailty accelerates with age and smoking compounds biological aging, preventive measures targeting this intersection could substantially alleviate the burden of respiratory disease in aging populations worldwide. The identification of epigenetic aging markers as correlates of frailty also opens avenues for novel biomarker-guided therapies and precision medicine approaches tailored to biological age rather than chronological age alone.

This study forms part of a growing body of evidence reshaping clinical approaches to chronic respiratory diseases. Traditionally, COPD management has been heavily reliant on lung function thresholds, but the current research highlights that frailty and biological aging metrics provide crucial additional layers of prognostic information. Such multidimensional assessments may pave the way for more nuanced, personalized interventions that address the systemic nature of respiratory vulnerability among smokers and ex-smokers.

In conclusion, the extensive analysis from the COPDGene cohort reinforces frailty as a critical determinant of respiratory morbidity and mortality beyond lung mechanics. The demonstrated link between frailty, respiratory exacerbations, and accelerated epigenetic aging presents a paradigm shift in understanding respiratory health in smokers, advocating for the integration of frailty screening into routine clinical evaluation. As the population ages and reaches higher cumulative tobacco exposure, adopting frailty-informed models of care could revolutionize prevention and management strategies, ultimately saving lives.

The potential for frailty screening to serve as a sentinel marker for impending respiratory decline invites further investigation into mechanistic pathways and therapeutic targets. Future research could explore how interventions aimed at modulating biological aging might impact frailty severity and respiratory outcomes, potentially curbing the trajectory of respiratory diseases linked to smoking. This translational bridge between molecular aging biology and clinical respiratory medicine heralds an exciting frontier in pulmonary health.

Overall, the study by Phillips et al. represents a critical advancement in respiratory medicine, merging clinical gerontology, molecular biology, and pulmonology. It underscores the imperative to look beyond conventional diagnostics and embrace a holistic view of patient vulnerability, particularly in populations burdened by smoking exposure. With mounting evidence, frailty screening is poised to become an indispensable component of respiratory risk assessment and personalized medicine.

Subject of Research: People

Article Title: Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort

News Publication Date: 3-Jul-2025

Web References: http://dx.doi.org/10.18632/aging.206275

Image Credits: Copyright: © 2025 Phillips et al. Distributed under Creative Commons Attribution License (CC BY 4.0).

Keywords: aging, frailty, cigarette smoking, respiratory exacerbations, COPD, epigenetic aging

Breast cancer, a major global health concern, demands continuously evolving screening programs to improve early detection and reduce mortality. This investigation specifically targets the female population in Wu Wei, providing a regional lens that encapsulates socioeconomic and behavioral variables rarely examined in concert before. With a detection rate of approximately 20% for breast-related diseases among participants, researchers have managed to construct a nuanced model illustrating how smoking mediates and exacerbates risks, especially when intersecting with education levels.

The authors employed Anderson’s model to create a pathway analysis that identifies direct and indirect effects of smoking on screening outcomes. Anderson’s framework, widely recognized for its utility in healthcare utilization studies, allows for detailed examination of predisposing characteristics, enabling behaviors, and health outcomes. By deploying this analytical approach, the research transcends simple correlation studies, revealing smoking’s role as both a direct contributor to pathological detection and a mediator modulated by educational attainment.

Data spanning 2021 to 2023 incorporated 1,792 female residents undergoing breast cancer screening, out of which 353 women were diagnosed with breast-related conditions. Such robust sample size lends credibility and statistical power to the findings. The researchers meticulously applied confirmatory factor and path analyses to validate the model, resulting in exceptionally strong fit indices (RMSEA <0.001, CFI=1.000, TLI=1.001, SRMR=0.024), underlining the reliability of their complex multivariate model.

One of the most striking revelations is the inverse relationship between education and breast disease detection linked via smoking behavior. Women with lower educational attainment were significantly more likely to smoke, and this habit substantially increased their risk of breast-related lesion detection. The path coefficient indicating the direct effect of smoking was negative (-0.105), suggesting that smoking not only contributes to higher detection rates but also serves as a critical mediating factor in the impact of education on screening outcomes.

The study elucidates how smoking operates beyond a standalone risk factor, mediating educational disparities in health outcomes. Specifically, smoking mediates an indirect effect size of -0.016 between education and lesion detection, signifying that smoking behaviors partially explain why lower education correlates with worse screening findings. This insight is particularly valuable for public health professionals aiming to target intervention programs more effectively.

From a methodological standpoint, the researchers implemented a rigorous single-factor analysis before constructing the pathway model, ensuring only statistically significant variables informed the final model. This precision strengthens the trustworthiness of the conclusions and provides a replicable framework for future studies in other demographics or regions. It highlights an innovative approach to integrating behavioral and sociodemographic factors within screening outcome research.

The implications for regional healthcare policy are profound. The study recommends enhanced community-based smoking cessation programs tailored to women with lower educational levels, as these groups face compounded risks. Moreover, the findings urge healthcare providers in Wu Wei and similar settings to optimize breast cancer screening strategies by incorporating behavioral risk assessments, fostering a more personalized preventive healthcare system.

With its compelling evidence, the research prompts a reconsideration of how breast cancer screening programs define and address risk stratification. Rather than employing generic criteria, integrating behavioral factors like smoking status could allow more precise identification of high-risk individuals. This would result in earlier diagnoses, improved prognosis, and ultimately, reduced cancer-related mortality rates.

Importantly, the findings also fuel broader conversations about health education’s role in preventive outcomes. The clear association between lower education and increased smoking prevalence emphasizes the urgent need for comprehensive health literacy initiatives. Targeted education can empower women, particularly in rural or socioeconomically disadvantaged regions, to make healthier lifestyle choices, significantly impacting cancer screening success.

While the study centers on Wu Wei, its methodology and outcomes resonate on a global scale. Many countries grapple with disparities in cancer detection tied to socioeconomic and behavioral factors. This research contributes a replicable template by coupling epidemiological data with behavioral theory, which may be adapted to diverse cultural and healthcare environments to sharpen breast cancer screening efficacy worldwide.

Technically, the study’s pathway model showcases the utility of advanced statistical techniques in unraveling multi-dimensional health issues. Fit indices such as CFI and TLI exceeding 1.0 are rare and indicate an exceptional model fit, underscoring the robustness of the constructed framework. These statistical validations provide confidence that the identified pathways—especially involving smoking—are not artifacts but rather genuine relationships embedded in the population.

Looking ahead, the authors suggest that future research should explore longitudinal tracking of smoking cessation efforts alongside breast cancer screening outcomes to assess the long-term impact of behavioral interventions. Combining molecular biomarkers with behavioral data may also deepen understanding of how smoking biologically influences tumorigenesis and lesion development detected during screenings.

The study sets a new benchmark in integrating behavioral epidemiology with clinical oncology screening. By substantiating the profound influence of smoking as both a direct risk and a socioeconomic mediator, the research underscores the necessity of intersectoral collaboration. Public health officials, clinicians, and educators must unite to deploy multifaceted approaches that address lifestyle modification, enhance educational outreach, and refine screening protocols tailored to vulnerable populations.

In sum, this pioneering study offers a vital lens into how smoking compromises breast cancer screening outcomes in the female population of Wu Wei, China. By illuminating the intricate pathways connecting education, smoking, and lesion detection, the research paves the way for smarter, data-driven approaches to cancer prevention. Its findings are a call to action for healthcare systems worldwide to incorporate behavioral insights into screening strategies and public health programming.

Subject of Research: The impact of smoking on breast cancer screening results in women, particularly examining how smoking mediates the relationship between education and detection of breast-related lesions.

Article Title: The effect of smoking on breast cancer screening results in female population: a study in Wu Wei, China

Article References:
Sun, Q., Hu, J., Ye, Y. et al. The effect of smoking on breast cancer screening results in female population: a study in Wu Wei, China. BMC Cancer 25, 1225 (2025). https://doi.org/10.1186/s12885-025-14586-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14586-y